NCT05269290View on ClinicalTrials.gov

Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

April 29, 2022

Study Completion Date

July 15, 2022

Conditions
Influenza, HumanAcute Respiratory InfectionCommon Cold
Interventions
DRUG

Ingavirin®, syrup, 30 mg/5 ml

A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.

DRUG

Placebo

Placebo will be administered once a day on top of standard therapy.

Trial Locations (8)

191144

"St. Petersburg State Budgetary Healthcare Institution Children's City Polyclinic No. 44", Saint Petersburg

193312

City Polyclinic No. 45 of Nevsky District, Saint Petersburg

196158

PiterKlinika LLC, Saint Petersburg

214031

Uromed LLC, Smolensk

450008

Bashkir State Medical University, Ufa

614066

City Pediatric Outpatient Clinic number 5, Perm

614070

Professors' Clinic LLC., Perm

1430010

Federal Research and Clinical Center of Physical and Chemical Medicine of the Federal Medical and Biological Agency, Odintsovo

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY

NCT05269290 - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections | Biotech Hunter | Biotech Hunter